Armin Rauschenberger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Armin Rauschenberger has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Enrico Glaab
Biomedical Data Science Group, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg
13 shared publications - Rejko Krüger
Luxembourg Institute of Health
8 shared publications - Lukas Pavelka
Luxembourg Institute of Health (LIH)
5 shared publications - Mark A. van de Wiel
Department of Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam University Medical Centers, Amsterdam, The Netherlands
5 shared publications - Anja K. Leist
Department of Social Sciences, University of Luxembourg, Esch-sur-Alzette, Luxembourg
3 shared publications - Anne-Marie Hanff
Transversal Translational Medicine, Luxembourg Institute of Health, Strassen, Luxembourg
3 shared publications
Latest Publications
- Open Access
Sex-specific microRNA regulators of Parkinson’s disease: insights from cohort-stratified simulations of compensatory pathway dynamics
Parkinson’s disease (PD) exhibits sex differences in prevalence, symptom severity, and progression, suggesting distinct underlying molecular mechanisms. However, the pathophysiological mechanisms remain largely obscure, particularly in the context of the post-transcriptional regulations, where microRNAs (miRNAs) suppress the expression of multiple genes. Bulk transcriptomic data often blur these effects, especially when regulatory patterns vary by sex or cell type. miRNAs have emerged as key regulators of PD-related processes, but their complexity demands computational methods that enable capturing the functional impact at the pathway level. In this study, we investigated how sex may affect miRNA-regulated PD pathways using Boolean modeling across two large PD cohorts, the Parkinson’s Progression Markers Initiative (PPMI) and the Luxembourg Parkinson’s Study (LuxPark). First, differential expression analysis identified significant variations in miRNA expression between the sexes across both cohorts. These miRNAs were analysed to identify molecular pathways that are over-represented among the predicted targets of the dysregulated microRNAs (i.e. enrichment analysis). The enriched pathways were used to build Boolean models to simulate the effects of sex-specific miRNA dysregulation. These simulations showed consistent male-specific impairment in mitochondrial biogenesis, and respiratory chain activity. Mitophagy and oxidative stress response pathways were also disrupted, alongside dysregulation of autophagy-related protein-folding mechanisms. Our findings suggest that sex-specific miRNA dysregulation contributes to differences in molecular patterns in PD by influencing compensatory related pathways and responses. These results highlight the need for sex-stratified approaches in modeling, translational research, and precision medicine strategies for disease-modifying treatments.
Open AccessSex-specific microRNA regulators of Parkinson’s disease: insights from cohort-stratified simulations of compensatory pathway dynamics
Parkinson’s disease (PD) exhibits sex differences in prevalence, symptom severity, and progression, suggesting distinct underlying molecular mechanisms. However, the pathophysiological mechanisms remain largely obscure, particularly in the context of the post-transcriptional regulations, where microRNAs (miRNAs) suppress the expression of multiple genes. Bulk transcriptomic data often blur these effects, especially when regulatory patterns vary by sex or cell type. miRNAs have emerged as key regulators of PD-related processes, but their complexity demands computational methods that enable capturing the functional impact at the pathway level. In this study, we investigated how sex may affect miRNA-regulated PD pathways using Boolean modeling across two large PD cohorts, the Parkinson’s Progression Markers Initiative (PPMI) and the Luxembourg Parkinson’s Study (LuxPark). First, differential expression analysis identified significant variations in miRNA expression between the sexes across both cohorts. These miRNAs were analysed to identify molecular pathways that are over-represented among the predicted targets of the dysregulated microRNAs (i.e. enrichment analysis). The enriched pathways were used to build Boolean models to simulate the effects of sex-specific miRNA dysregulation. These simulations showed consistent male-specific impairment in mitochondrial biogenesis, and respiratory chain activity. Mitophagy and oxidative stress response pathways were also disrupted, alongside dysregulation of autophagy-related protein-folding mechanisms. Our findings suggest that sex-specific miRNA dysregulation contributes to differences in molecular patterns in PD by influencing compensatory related pathways and responses. These results highlight the need for sex-stratified approaches in modeling, translational research, and precision medicine strategies for disease-modifying treatments.
- Open Access
- 17 July 2025
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 41 (10)
Estimating sparse regression models in multi-task learning and transfer learning through adaptive penalisation
Method: Here, we propose a simple two-stage procedure for sharing information between related high-dimensional prediction or classification problems. In both stages, we perform sparse regression separately for each problem. While this is done without prior information in the first stage, we use the coefficients from the first stage as prior information for the second stage. Specifically, we designed feature-specific and sign-specific adaptive weights to share information on feature selection, effect directions, and effect sizes between different problems. Results: The proposed approach is applicable to multi-task learning as well as transfer learning. It provides sparse models (i.e. with few non-zero coefficients for each problem) that are easy to interpret. We show by simulation and application that it tends to select fewer features while achieving a similar predictive performance as compared to available methods. Availability and implementation: An implementation is available in the R package “sparselink” (https://github.com/rauschenberger/sparselink, https://cran.r-project.org/package=sparselink).
- 17 July 2025
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 41 (10)
Open AccessEstimating sparse regression models in multi-task learning and transfer learning through adaptive penalisation
Method: Here, we propose a simple two-stage procedure for sharing information between related high-dimensional prediction or classification problems. In both stages, we perform sparse regression separately for each problem. While this is done without prior information in the first stage, we use the coefficients from the first stage as prior information for the second stage. Specifically, we designed feature-specific and sign-specific adaptive weights to share information on feature selection, effect directions, and effect sizes between different problems. Results: The proposed approach is applicable to multi-task learning as well as transfer learning. It provides sparse models (i.e. with few non-zero coefficients for each problem) that are easy to interpret. We show by simulation and application that it tends to select fewer features while achieving a similar predictive performance as compared to available methods. Availability and implementation: An implementation is available in the R package “sparselink” (https://github.com/rauschenberger/sparselink, https://cran.r-project.org/package=sparselink).
- 3 June 2025
- Published by The R Foundation
sparselink: Sparse Regression for Related Problems
Estimates sparse regression models (i.e., with few non-zero coefficients) in high-dimensional multi-task learning and transfer learning settings, as proposed by Rauschenberger et al. (2025) .
- 3 June 2025
- Published by The R Foundation
sparselink: Sparse Regression for Related Problems
Estimates sparse regression models (i.e., with few non-zero coefficients) in high-dimensional multi-task learning and transfer learning settings, as proposed by Rauschenberger et al. (2025) .
- Open Access
- 19 May 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (4) , 805-818
Sex-specific progression of Parkinson's disease: A longitudinal mixed-models analysis
Background: Despite its relevance, the clinical progression of motor- and non-motor symptoms associated with Parkinson's disease (PD) is poorly described and understood, particularly in relation to sex-specific differences in clinical progression. Objective: Identification of differential aspects in disease progression in men and women with PD. Methods: Linear mixed-model analyses of 802 people with typical PD from the Luxembourg Parkinson's study's prospective cohort (median time of follow-up = three years). We estimated the effect of time and its moderation by sex (alpha ≤ 0.05), including confidence intervals, for the following outcomes: MDS-UPDRS I-IV, Starkstein Apathy Scale, Beck Depression Inventory, Montreal Cognitive Assessment (MoCA), Sniffin’ sticks, bodily discomfort, rapid eye movement sleep behavior disorder questionnaire, PD Sleep Scale (PDSS), Munich Dysphagia Test-PD, Functional Mobility Composite Score, and the MDS-based tremor and postural instability and gait disturbances scale. In addition, the marginal means illustrated the symptoms’ trajectories in men and women. Men and women had similar age. Results: Overall, we observed a slower progression (interaction effect) in women compared to men, especially for MoCA (−0.159, 95%CI [−0.272, −0.046], p = 0.006), PDSS (−0.716, 95%CI [−1.229, −0.203], p = 0.006), PIGD (0.133, 95%CI [0.025 0.241], p = 0.016), and MDS-UPDRS II (0.346, 95%CI [0.120, 0.572], p = 0.003). The finding for MDS-UPDRS II was significant (FWER of 5%) after adjustment for multiple comparisons (Bonferroni-Holm). Conclusions: Next to the further exploration of sex-specific progression, interventions, proactive monitoring and communication strategies tailored to the symptoms progression and needs of men and women need to be developed.
- 19 May 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (4) , 805-818
Open AccessSex-specific progression of Parkinson's disease: A longitudinal mixed-models analysis
Background: Despite its relevance, the clinical progression of motor- and non-motor symptoms associated with Parkinson's disease (PD) is poorly described and understood, particularly in relation to sex-specific differences in clinical progression. Objective: Identification of differential aspects in disease progression in men and women with PD. Methods: Linear mixed-model analyses of 802 people with typical PD from the Luxembourg Parkinson's study's prospective cohort (median time of follow-up = three years). We estimated the effect of time and its moderation by sex (alpha ≤ 0.05), including confidence intervals, for the following outcomes: MDS-UPDRS I-IV, Starkstein Apathy Scale, Beck Depression Inventory, Montreal Cognitive Assessment (MoCA), Sniffin’ sticks, bodily discomfort, rapid eye movement sleep behavior disorder questionnaire, PD Sleep Scale (PDSS), Munich Dysphagia Test-PD, Functional Mobility Composite Score, and the MDS-based tremor and postural instability and gait disturbances scale. In addition, the marginal means illustrated the symptoms’ trajectories in men and women. Men and women had similar age. Results: Overall, we observed a slower progression (interaction effect) in women compared to men, especially for MoCA (−0.159, 95%CI [−0.272, −0.046], p = 0.006), PDSS (−0.716, 95%CI [−1.229, −0.203], p = 0.006), PIGD (0.133, 95%CI [0.025 0.241], p = 0.016), and MDS-UPDRS II (0.346, 95%CI [0.120, 0.572], p = 0.003). The finding for MDS-UPDRS II was significant (FWER of 5%) after adjustment for multiple comparisons (Bonferroni-Holm). Conclusions: Next to the further exploration of sex-specific progression, interventions, proactive monitoring and communication strategies tailored to the symptoms progression and needs of men and women need to be developed.
- Open Access
- 9 May 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (5) , e0320196
Waning of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in 2020: A 12-month-evaluation in three population-based European studies
Objectives: We described waning in anti-SARS-CoV-2 IgG in adult general populations infected during the first wave of the COVID-19 pandemic in 2020 across three European countries. Methods: Coordinated analyses were conducted separately in three population-based cohorts with complementary follow-up schedules: the KoCo19 (Germany), EpiCov (France), and CON-VINCE (Luxembourg) cohorts. Serological follow-up was based on the anti-SARS-CoV-2 ELISA-S IgG (Euroimmun) assay. We selected all adults aged 18–79 who had a positive serology (IgG optical density (OD) ratio ≥1.1) between February and July 2020, and at least one subsequent IgG measurement within the following 12 months, while still non-vaccinated. Results: The proportion of seroreversion was 0% within the four first months, based on Koco19 data (n = 65 participants). In the longer term, 31.3% of participants had seroreverted at 6 months (95%CI: 24.4–39.1) (based on EpiCov data, n = 599), 31.3% (95%CI: 11.0–58.7) at 12 months (based on CON-VINCE data, n = 16). From EpiCov data, both baseline low IgG levels and seroneutralization negativity remained predictive of seroreversion in multivariable analysis. Conclusion: From population-based cohorts, anti-S IgG levels remained stable during the first 4 months following SARS-CoV-2 infection. Most of the decay occurred afterward; nearly one-third of people seroreverted 6 and 12 months later. Low IgG levels and seroneutralization negativity were independent predictors of seroreversion.
- 9 May 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (5) , e0320196
Open AccessWaning of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in 2020: A 12-month-evaluation in three population-based European studies
Objectives: We described waning in anti-SARS-CoV-2 IgG in adult general populations infected during the first wave of the COVID-19 pandemic in 2020 across three European countries. Methods: Coordinated analyses were conducted separately in three population-based cohorts with complementary follow-up schedules: the KoCo19 (Germany), EpiCov (France), and CON-VINCE (Luxembourg) cohorts. Serological follow-up was based on the anti-SARS-CoV-2 ELISA-S IgG (Euroimmun) assay. We selected all adults aged 18–79 who had a positive serology (IgG optical density (OD) ratio ≥1.1) between February and July 2020, and at least one subsequent IgG measurement within the following 12 months, while still non-vaccinated. Results: The proportion of seroreversion was 0% within the four first months, based on Koco19 data (n = 65 participants). In the longer term, 31.3% of participants had seroreverted at 6 months (95%CI: 24.4–39.1) (based on EpiCov data, n = 599), 31.3% (95%CI: 11.0–58.7) at 12 months (based on CON-VINCE data, n = 16). From EpiCov data, both baseline low IgG levels and seroneutralization negativity remained predictive of seroreversion in multivariable analysis. Conclusion: From population-based cohorts, anti-S IgG levels remained stable during the first 4 months following SARS-CoV-2 infection. Most of the decay occurred afterward; nearly one-third of people seroreverted 6 and 12 months later. Low IgG levels and seroneutralization negativity were independent predictors of seroreversion.
- Open Access
- 3 May 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 6 (3) , fcae187
Converging peripheral blood microRNA profiles in Parkinson's disease and progressive supranuclear palsy
MicroRNAs act via targeted suppression of messenger RNA translation in the DNA–RNA–protein axis. The dysregulation of microRNA(s) reflects the epigenetic changes affecting the cellular processes in multiple disorders. To understand the complex effect of dysregulated microRNAs linked to neurodegeneration, we performed a cross-sectional microRNA expression analysis in idiopathic Parkinson's disease (n = 367), progressive supranuclear palsy (n = 35) and healthy controls (n = 416) from the Luxembourg Parkinson's Study, followed by prediction modelling, enriched pathway analysis and target simulation of dysregulated microRNAs using probabilistic Boolean modelling. Forty-six microRNAs were identified to be dysregulated in Parkinson's disease versus controls and 16 in progressive supranuclear palsy versus controls with 4 overlapping significantly dysregulated microRNAs between the comparisons. Predictive power of microRNA subsets (including up to 100 microRNAs) was modest for differentiating Parkinson's disease or progressive supranuclear palsy from controls (maximal cross-validated area under the receiver operating characteristic curve 0.76 and 0.86, respectively) and low for progressive supranuclear palsy versus Parkinson's disease (maximal cross-validated area under the receiver operating characteristic curve 0.63). The enriched pathway analysis revealed natural killer cell pathway to be dysregulated in both, Parkinson's disease and progressive supranuclear palsy versus controls, indicating that the immune system might play an important role in both diseases. Probabilistic Boolean modelling of pathway dynamics affected by dysregulated microRNAs in Parkinson's disease and progressive supranuclear palsy revealed partially overlapping dysregulation in activity of the transcription factor EB, endoplasmic reticulum stress signalling, calcium signalling pathway, dopaminergic transcription and peroxisome proliferator-activated receptor gamma coactivator-1α activity, though involving different mechanisms. These findings indicated a partially convergent (sub)cellular end-point dysfunction at multiple levels in Parkinson's disease and progressive supranuclear palsy, but with distinctive underlying molecular mechanisms.
- 3 May 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 6 (3) , fcae187
Open AccessConverging peripheral blood microRNA profiles in Parkinson's disease and progressive supranuclear palsy
MicroRNAs act via targeted suppression of messenger RNA translation in the DNA–RNA–protein axis. The dysregulation of microRNA(s) reflects the epigenetic changes affecting the cellular processes in multiple disorders. To understand the complex effect of dysregulated microRNAs linked to neurodegeneration, we performed a cross-sectional microRNA expression analysis in idiopathic Parkinson's disease (n = 367), progressive supranuclear palsy (n = 35) and healthy controls (n = 416) from the Luxembourg Parkinson's Study, followed by prediction modelling, enriched pathway analysis and target simulation of dysregulated microRNAs using probabilistic Boolean modelling. Forty-six microRNAs were identified to be dysregulated in Parkinson's disease versus controls and 16 in progressive supranuclear palsy versus controls with 4 overlapping significantly dysregulated microRNAs between the comparisons. Predictive power of microRNA subsets (including up to 100 microRNAs) was modest for differentiating Parkinson's disease or progressive supranuclear palsy from controls (maximal cross-validated area under the receiver operating characteristic curve 0.76 and 0.86, respectively) and low for progressive supranuclear palsy versus Parkinson's disease (maximal cross-validated area under the receiver operating characteristic curve 0.63). The enriched pathway analysis revealed natural killer cell pathway to be dysregulated in both, Parkinson's disease and progressive supranuclear palsy versus controls, indicating that the immune system might play an important role in both diseases. Probabilistic Boolean modelling of pathway dynamics affected by dysregulated microRNAs in Parkinson's disease and progressive supranuclear palsy revealed partially overlapping dysregulation in activity of the transcription factor EB, endoplasmic reticulum stress signalling, calcium signalling pathway, dopaminergic transcription and peroxisome proliferator-activated receptor gamma coactivator-1α activity, though involving different mechanisms. These findings indicated a partially convergent (sub)cellular end-point dysfunction at multiple levels in Parkinson's disease and progressive supranuclear palsy, but with distinctive underlying molecular mechanisms.
- Open Access
- 19 March 2024
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 10 (1) , 1-18
Comprehensive blood metabolomics profiling of Parkinson’s disease reveals coordinated alterations in xanthine metabolism
Parkinson’s disease (PD) is a highly heterogeneous disorder influenced by several environmental and genetic factors. Effective disease-modifying therapies and robust early-stage biomarkers are still lacking, and an improved understanding of the molecular changes in PD could help to reveal new diagnostic markers and pharmaceutical targets. Here, we report results from a cohort-wide blood plasma metabolic profiling of PD patients and controls in the Luxembourg Parkinson’s Study to detect disease-associated alterations at the level of systemic cellular process and network alterations. We identified statistically significant changes in both individual metabolite levels and global pathway activities in PD vs. controls and significant correlations with motor impairment scores. As a primary observation when investigating shared molecular sub-network alterations, we detect pronounced and coordinated increased metabolite abundances in xanthine metabolism in de novo patients, which are consistent with previous PD case/control transcriptomics data from an independent cohort in terms of known enzyme-metabolite network relationships. From the integrated metabolomics and transcriptomics network analysis, the enzyme hypoxanthine phosphoribosyltransferase 1 (HPRT1) is determined as a potential key regulator controlling the shared changes in xanthine metabolism and linking them to a mechanism that may contribute to pathological loss of cellular adenosine triphosphate (ATP) in PD. Overall, the investigations revealed significant PD-associated metabolome alterations, including pronounced changes in xanthine metabolism that are mechanistically congruent with alterations observed in independent transcriptomics data. The enzyme HPRT1 may merit further investigation as a main regulator of these network alterations and as a potential therapeutic target to address downstream molecular pathology in PD.
- 19 March 2024
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 10 (1) , 1-18
Open AccessComprehensive blood metabolomics profiling of Parkinson’s disease reveals coordinated alterations in xanthine metabolism
Parkinson’s disease (PD) is a highly heterogeneous disorder influenced by several environmental and genetic factors. Effective disease-modifying therapies and robust early-stage biomarkers are still lacking, and an improved understanding of the molecular changes in PD could help to reveal new diagnostic markers and pharmaceutical targets. Here, we report results from a cohort-wide blood plasma metabolic profiling of PD patients and controls in the Luxembourg Parkinson’s Study to detect disease-associated alterations at the level of systemic cellular process and network alterations. We identified statistically significant changes in both individual metabolite levels and global pathway activities in PD vs. controls and significant correlations with motor impairment scores. As a primary observation when investigating shared molecular sub-network alterations, we detect pronounced and coordinated increased metabolite abundances in xanthine metabolism in de novo patients, which are consistent with previous PD case/control transcriptomics data from an independent cohort in terms of known enzyme-metabolite network relationships. From the integrated metabolomics and transcriptomics network analysis, the enzyme hypoxanthine phosphoribosyltransferase 1 (HPRT1) is determined as a potential key regulator controlling the shared changes in xanthine metabolism and linking them to a mechanism that may contribute to pathological loss of cellular adenosine triphosphate (ATP) in PD. Overall, the investigations revealed significant PD-associated metabolome alterations, including pronounced changes in xanthine metabolism that are mechanistically congruent with alterations observed in independent transcriptomics data. The enzyme HPRT1 may merit further investigation as a main regulator of these network alterations and as a potential therapeutic target to address downstream molecular pathology in PD.
- Open Access
- 23 November 2023
- Published by Elsevier in Gait & Posture
- Vol. 108, 97-109
Determinants of patient-reported functional mobility in people with Parkinson's disease: A systematic review
- 23 November 2023
- Published by Elsevier in Gait & Posture
- Vol. 108, 97-109
Open AccessDeterminants of patient-reported functional mobility in people with Parkinson's disease: A systematic review
- Open Access
- 10 November 2023
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 39 (12)
Penalized regression with multiple sources of prior effects
Motivation: In many high-dimensional prediction or classification tasks, complementary data on the features are available, e.g. prior biological knowledge on (epi)genetic markers. Here we consider tasks with numerical prior information that provide an insight into the importance (weight) and the direction (sign) of the feature effects, e.g. regression coefficients from previous studies. Results: We propose an approach for integrating multiple sources of such prior information into penalized regression. If suitable co-data are available, this improves the predictive performance, as shown by simulation and application. Availability and implementation: The proposed method is implemented in the R package transreg (https://github.com/lcsb-bds/transreg, https://cran.r-project.org/package=transreg).
- 10 November 2023
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 39 (12)
Open AccessPenalized regression with multiple sources of prior effects
Motivation: In many high-dimensional prediction or classification tasks, complementary data on the features are available, e.g. prior biological knowledge on (epi)genetic markers. Here we consider tasks with numerical prior information that provide an insight into the importance (weight) and the direction (sign) of the feature effects, e.g. regression coefficients from previous studies. Results: We propose an approach for integrating multiple sources of such prior information into penalized regression. If suitable co-data are available, this improves the predictive performance, as shown by simulation and application. Availability and implementation: The proposed method is implemented in the R package transreg (https://github.com/lcsb-bds/transreg, https://cran.r-project.org/package=transreg).
- 1 October 2023
- Published by The R Foundation
transreg: Penalised Regression with Multiple Sets of Prior Effects ('Transfer Learning')
- 1 October 2023
- Published by The R Foundation
transreg: Penalised Regression with Multiple Sets of Prior Effects ('Transfer Learning')